Publications

Detailed Information

Estrogen Receptor-1 Genetic Polymorphisms for the Risk of Premature Ovarian Failure and Early Menopause

DC Field Value Language
dc.contributor.authorYang, Jae Jeong-
dc.contributor.authorCho, Lisa Y.-
dc.contributor.authorLim, Yun Jeong-
dc.contributor.authorKo, Kwang-Pil-
dc.contributor.authorKim, Hyeongsu-
dc.contributor.authorChang, Soung Hoon-
dc.contributor.authorPark, Sue K.-
dc.contributor.authorYim, Sung Vin-
dc.contributor.authorLee, Kun-Sei-
dc.date.accessioned2012-06-08T06:37:55Z-
dc.date.available2012-06-08T06:37:55Z-
dc.date.issued2010-02-
dc.identifier.citationJOURNAL OF WOMENS HEALTH; Vol.19 2; 297-304ko_KR
dc.identifier.issn1540-9996-
dc.identifier.urihttps://hdl.handle.net/10371/76910-
dc.description.abstractBackground: The aim of this study was to investigate the role of the estrogen receptor 1 (ESR1) genetic polymorphisms for early menopause that was classified as premature ovarian failure (POF) and early menopause (EM) and to examine whether the associations of ESR1 genetic variants are different for POF and EM. Methods: We selected 100 POF cases and matched 100 EM cases and 200 normal menopause (NM) controls from the Korean Multi-Center Cohort. Among them, we restricted idiopathic POF and EM cases vs NM controls by excluding POF/EM cases with medical/surgical causes. The XbaI (rs9340799) and PvuII (rs2234693) in the ESR1 gene were genotyped. The single-nucleotide polymorphism (SNP) and haplotype effects were analyzed by multivariate logistic regression and haplotype analysis. Also nominal polytomous logistic regression was used to find whether ESR1 genetic variants are differently associated with POF and EM. Results: The global p values for idiopathic POF and EM were 0.08 and 0.39 (SNP-based), and <0.001 and 0.12 (haplotype-based), respectively. The XbaI genetic variant containing the X allele was marginally significantly associated with a reduced risk of idiopathic POF (OR=0.6, 95% CI 0.3-1.0). The P-x haplotype and diplotypes significantly decreased the risk of idiopathic POF (OR=0.5, 95% CI 0.2-0.9; OR 0.4, 95% CI 0.2-0.9, respectively). In contrast from POF, the P-x haplotypes and diplotypes insignificantly increased the risk for both idiopathic EM (p(polytomous)=0.009 for P-x haplotype; p(polytomous)=0.02 for P-x diplotypes). Conclusion: Our results suggest that the ESR1 gene including PvuII and XbaI polymorphisms may modify the risk of idiopathic premature ovarian failure (POF) but not idiopathic early menopause (EM) risk.ko_KR
dc.language.isoenko_KR
dc.publisherMARY ANN LIEBERT INCko_KR
dc.titleEstrogen Receptor-1 Genetic Polymorphisms for the Risk of Premature Ovarian Failure and Early Menopauseko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor양재정-
dc.contributor.AlternativeAuthor임윤정-
dc.contributor.AlternativeAuthor고광필-
dc.contributor.AlternativeAuthor이건세-
dc.contributor.AlternativeAuthor김형수-
dc.contributor.AlternativeAuthor임성빈-
dc.contributor.AlternativeAuthor장성훈-
dc.contributor.AlternativeAuthor박수경-
dc.identifier.doi10.1089/jwh.2008.1317-
dc.citation.journaltitleJOURNAL OF WOMENS HEALTH-
dc.description.citedreferenceBretherick KL, 2008, FERTIL STERIL, V89, P318, DOI 10.1016/j.fertnstert.2007.03.008-
dc.description.citedreferenceChang SH, 2007, MATURITAS, V58, P19, DOI 10.1016/j.maturitas.2007.04.001-
dc.description.citedreferenceKitamura I, 2007, BONE, V40, P1623, DOI 10.1016/j.bone.2007.02.016-
dc.description.citedreferenceMolvarec A, 2007, HYPERTENS RES, V30, P205-
dc.description.citedreferenceHsieh YY, 2007, MOL HUM REPROD, V13, P117, DOI 10.1093/molehr/gal099-
dc.description.citedreferenceDvornyk V, 2006, MATURITAS, V54, P19, DOI 10.1016/j.maturitas.2005.08.005-
dc.description.citedreferenceOnland-Moret NC, 2005, CANCER CAUSE CONTROL, V16, P1195, DOI 10.1007/s10552-005-0307-5-
dc.description.citedreferencePopat RA, 2005, NEUROLOGY, V65, P383-
dc.description.citedreferenceSchuit SCE, 2005, EUR J ENDOCRINOL, V153, P327, DOI 10.1530/eje.1.01973-
dc.description.citedreferenceKok HS, 2005, HUM REPROD, V20, P536, DOI 10.1093/humrep/deh600-
dc.description.citedreferenceIoannidis JPA, 2004, JAMA-J AM MED ASSOC, V292, P2105-
dc.description.citedreferencevan der Klift M, 2004, J BONE MINER RES, V19, P1172, DOI 10.1359/JBMR.040215-
dc.description.citedreferenceSchuit SCE, 2004, JAMA-J AM MED ASSOC, V291, P2969-
dc.description.citedreferenceWasserman L, 2004, INT J OBESITY, V28, P49, DOI 10.1038/sj.ijo.0802481-
dc.description.citedreferencevan Meurs JBJ, 2003, HUM MOL GENET, V12, P1745, DOI 10.1093/hmg/ddg176-
dc.description.citedreferenceGorai I, 2003, J CLIN ENDOCR METAB, V88, P799, DOI 10.1210/jc.2002-020353-
dc.description.citedreferenceLaml T, 2002, HUM REPROD UPDATE, V8, P483-
dc.description.citedreferenceHerrington DM, 2002, CIRCULATION, V105, P1879, DOI 10.1161/01.CIR.0000016173.98826.88-
dc.description.citedreferenceKobayashi N, 2002, MATURITAS, V41, P193-
dc.description.citedreferenceYOO KY, 2002, ASIAN PAC J CANCER P, V3, P85-
dc.description.citedreferencede Bruin JP, 2001, HUM REPROD, V16, P2014-
dc.description.citedreferencePelletier G, 2000, J CLIN ENDOCR METAB, V85, P4835-
dc.description.citedreferenceWeiderpass E, 2000, CARCINOGENESIS, V21, P623-
dc.description.citedreferenceYan G, 2000, J WOMEN HEALTH GEN-B, V9, P275-
dc.description.citedreferenceLorentzon M, 1999, J CLIN ENDOCR METAB, V84, P4597-
dc.description.citedreferenceWeel AEAM, 1999, J CLIN ENDOCR METAB, V84, P3146-
dc.description.citedreferenceDrummond AE, 1999, MOL CELL ENDOCRINOL, V151, P57, DOI 10.1016/S0303-7207(99)00038-6-
dc.description.citedreferenceChristin-Maitre S, 1998, MOL CELL ENDOCRINOL, V145, P75-
dc.description.citedreferenceTorgerson DJ, 1997, EUR J OBSTET GYN R B, V74, P63-
dc.description.citedreferencevanderSchouw YT, 1996, LANCET, V347, P714-
dc.description.citedreferenceKobayashi S, 1996, J BONE MINER RES, V11, P306-
dc.description.citedreferenceNELSON LM, 1996, REPROD ENDOCRINOLOGY, P1394-
dc.description.citedreferenceKAPRIO J, 1995, HUM BIOL, V67, P739-
dc.description.citedreferenceCRAMER DW, 1995, FERTIL STERIL, V64, P740-
dc.description.citedreferenceEXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921-
dc.description.citedreferenceNELSON LM, 1994, J CLIN ENDOCR METAB, V79, P1470-
dc.description.citedreferenceCAPLAN GA, 1994, J ROY SOC MED, V87, P200-
dc.description.citedreferencePALMER JR, 1992, AM J EPIDEMIOL, V136, P408-
dc.description.citedreferenceBAGUR AC, 1992, CALCIFIED TISSUE INT, V51, P4-
dc.description.citedreferenceFRANCESCHI S, 1991, INT J CANCER, V49, P57-
dc.description.citedreferenceMEYER JM, 1991, AM J MED GENET, V39, P148-
dc.description.citedreferenceTRELOAR SA, 1990, AM J HUM GENET, V47, P137-
dc.description.citedreferenceSNOWDON DA, 1989, AM J PUBLIC HEALTH, V79, P709-
dc.description.tc3-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share